Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:NITE NYSE:PLX NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.67-2.3%$1.78$1.12▼$4.20$124.44M0.92186,770 shs209,450 shsNITENightstar Therapeutics$33.47+0.1%$25.41$9.59▼$29.55$1.12B2.84185,808 shs297 shsPLXProtalix BioTherapeutics$1.54-3.1%$1.53$0.98▼$3.10$122.79M-0.23826,638 shs1.20 million shsPRMEPrime Medicine$3.72+9.4%$3.77$1.11▼$5.17$457.55M2.382.53 million shs2.76 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-7.22%+7.74%-14.80%+23.70%NITENightstar Therapeutics+0.09%-0.18%+4.87%+13.98%+40.33%PLXProtalix BioTherapeutics0.00%-0.65%+1.99%-2.53%+52.48%PRMEPrime Medicine0.00%+14.81%+1.09%+120.12%-3.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.67-2.3%$1.78$1.12▼$4.20$124.44M0.92186,770 shs209,450 shsNITENightstar Therapeutics$33.47+0.1%$25.41$9.59▼$29.55$1.12B2.84185,808 shs297 shsPLXProtalix BioTherapeutics$1.54-3.1%$1.53$0.98▼$3.10$122.79M-0.23826,638 shs1.20 million shsPRMEPrime Medicine$3.72+9.4%$3.77$1.11▼$5.17$457.55M2.382.53 million shs2.76 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-7.22%+7.74%-14.80%+23.70%NITENightstar Therapeutics+0.09%-0.18%+4.87%+13.98%+40.33%PLXProtalix BioTherapeutics0.00%-0.65%+1.99%-2.53%+52.48%PRMEPrime Medicine0.00%+14.81%+1.09%+120.12%-3.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50289.22% UpsideNITENightstar Therapeutics 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00874.03% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92139.70% UpsideCurrent Analyst Ratings BreakdownLatest NITE, PRME, PLX, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ANITENightstar TherapeuticsN/AN/AN/AN/A$5.89 per shareN/APLXProtalix BioTherapeutics$61.95M1.98$0.09 per share17.80$0.47 per share3.28PRMEPrime Medicine$4.96M100.91N/AN/A$1.37 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ANITENightstar Therapeutics-$36.86M-$1.26N/AN/AN/AN/A-30.89%-27.65%N/APLXProtalix BioTherapeutics$8.31M$0.07N/A4.97N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4538.87%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85NITENightstar TherapeuticsN/A8.548.54PLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%NITENightstar Therapeutics32.83%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%NITENightstar TherapeuticsN/APLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableNITENightstar Therapeutics4733.54 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableNITE, PRME, PLX, and IKT HeadlinesRecent News About These CompaniesPrime Drink Group Terminates Rights Offering and Announces Private PlacementSeptember 4 at 7:05 PM | globenewswire.comPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comPrime Medicine, Inc. (PRME) Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 2, 2025 | seekingalpha.comPrime Medicine (NYSE:PRME) Stock Price Up 4.9% - Here's What HappenedAugust 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Has $8.25 Million Stake in Prime Medicine, Inc. $PRMEAugust 27, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comPositive Signs As Multiple Insiders Buy Prime Medicine StockAugust 20, 2025 | uk.finance.yahoo.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comAnalysts Set Expectations for Prime Medicine FY2025 EarningsAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Prime Medicine Cut by HC WainwrightAugust 16, 2025 | marketbeat.comChardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00August 10, 2025 | marketbeat.comPrime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial PositionAugust 8, 2025 | tipranks.comPRME Revenue Misses by 73%August 8, 2025 | aol.comAPrime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue EstimatesAugust 7, 2025 | zacks.comPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPrime Medicine Holds Special Stockholder MeetingAugust 5, 2025 | tipranks.comFriday’s Insider Trades: Key Buys and Sells in US Stocks RevealedAugust 4, 2025 | investing.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 SharesAugust 2, 2025 | insidertrades.comPrime Medicine Halts Sales Agreement ProspectusAugust 1, 2025 | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1, 2025 | finance.yahoo.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesAugust 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett’s Mystery Buy Revealed, and It’s a Big Bet on UNHBy Ryan Hasson | August 15, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025Travel Stocks Rally on Earnings—More Upside Ahead?By Gabriel Osorio-Mazilli | August 18, 2025Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a TrendBy Jeffrey Neal Johnson | August 26, 2025NITE, PRME, PLX, and IKT Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.67 -0.04 (-2.34%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Nightstar Therapeutics NASDAQ:NITENightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.Protalix BioTherapeutics NYSE:PLX$1.54 -0.05 (-3.14%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.56 +0.02 (+1.62%) As of 09/5/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$3.72 +0.32 (+9.41%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.80 +0.07 (+2.02%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
